Press Releases
February 29, 2024
57% of Consumers Will Stay with Their Bank, Unless Offered Attractive Incentives Elsewhere, Vericast Research Finds
The latest听听from Vericast found consumer loyalty to financial institutions (FI) is fragile and only remains if FIs continue to invest in offerings that help customers reach their financial goals.听 听
JANUARY 13, 2022
Essential Federal Credit Union Supercharges Member Digital Engagement with Vericast鈥檚 Account Advisor Powered by Ignite Sales
Account Advisor enables Essential FCU to provide a deeper, consistent, and differentiated member experience
July 19, 2024
SIGA Announces U.S. Government Procurement Order of $113 Million for Oral TPOXX庐
Exercise of Procurement Option under Current Contract Reflects Continuing Action to Enhance Orthopoxvirus Preparedness
JANUARY 18, 2022
SIGA Technologies to Participate in Edison Group鈥檚 Global Healthcare 鈥淥pen House鈥� Virtual Conference from January 25-27th, 2022
SIGA Technologies, Inc. , a commercial-stage pharmaceutical company focused on the health security market, announced today that it will be participating in Edison Group鈥檚 Open House Event, scheduled to take place virtually this month.
JANUARY 10, 2022
SIGA Technologies Receives Approval from the European Medicines Agency for Tecovirimat
Broader Indication to Include Smallpox, Monkeypox, Cowpox, and Vaccinia Complications
June 24, 2024
vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes
Cadisegliatin听is听a听potential听first-in-class听oral听liver听selective听glucokinase听activator听for听T1D,听which听has听been granted Breakthrough Therapy designation by the FDA for T1D
JANUARY 13, 2022
vTv Therapeutics Shares Updated Corporate Presentation
VTVT, a clinical-stage biopharmaceutical company committed to improving the quality of life for people with diabetes, is sharing its updated corporate presentation highlighting its lead program TTP399, a novel oral liver-selective glucokinase activator, as a transformative treatment in the reduction of hypoglycemic episodes for the global diabetes population.